They noted that an incidence of HCC greater than 0.4%/year and adherence to surveillance, which would be greater than 19.5% biannually, was required for the combination of ultrasound and AFP to be cost-effective when compared to no surveillance being carried out [65]. This evidence concerns the gene AFP and hepatocellular carcinoma.